Rheumatoid Arthritis
Conditions
Keywords
Observational study
Brief summary
This is a descriptive, ambispective, and single-site study in Colombia, which is designed to evaluate the adherence, persistence, and clinical outcomes (defined as the patient's disease activity and functional status) of RA patients within 40 weeks after the patient administered the first injection of the etanercept medication through the Smartclic® device. The study data seeks from medical records containing the Smartclic device injection log and pharmacy claims database available from an institution specialized in rheumatological care. The study will only include records of patients treated or starting treatment with etanercept and whose indicated autoinjection device has been Smartclic.
Detailed description
Non-interventional study: The clinical records of eligible patients will be identified by the rheumatologist from the patients who attended the rheumatologist visit or institutional training sessions according to the standard of care. Patients have been prescribed etanercept according to the standard of care, and Smartclic has been indicated as an administration method.
Interventions
DRUGEtaneracept Smartclic
The SmartClic® autoinjector is a reusable, electromechanical, and single-patient device for the administration of subcutaneously administered biologics.
Sponsors
Pfizer
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. * Patients aged ≥18 years with an established diagnosis of rheumatoid arthritis according to EULAR-ACR criteria recorded in medical record. * Patients who are on etanercept treatment and are being switched to Smartclic, or new etanercept patients that have been prescribed Smartclic® device (either in combination with a conventional synthetic DMARD or in monotherapy). * Medical records and pharmacy claims database of the IPS available after the index date for a period of 40 weeks.
Exclusion criteria
\- Any serious ongoing infections, pregnancy, or other social or medical conditions that are anticipated in the investigator's judgment to lead to discontinuation of etanercept administration with the device during the 40 weeks of data collection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adherence (Pharmacy claims source) | Baseline through week 40 | The percentage of patients with Percentage of days covered (PDC) ≥ 80% |
| Change From Baseline in Disease Activity Score Based on 28-joints Count with ESR (DAS28-ESR) at 40 week | Baseline, Week 40 | — |
| Change From Baseline in Functional status Based on Multidimensional Health Assessment Questionnaire (MDHAQ) at 40 week | Baseline, Weeks 40 | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Persistence | Week 40 | Number of days to discontinuation from the index date (date that the patient administered the first injection of the etanercept medication through the Smartclic device) |
| Adherence from Smartclic® injection log | Week 40 | Percentage of patients with administration ≥ 80% based on the injection log of the e-Device |
Countries
Colombia
Outcome results
None listed